Narva – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:42 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Narva – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Narva Hospital https://clinicaltrials.eu/site/narva-hospital/ Thu, 30 Apr 2026 09:22:54 +0000 https://clinicaltrials.eu/site/narva-hospital/ Study on the Effectiveness and Safety of CHF6001 DPI with Roflumilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-chf6001-dpi-with-roflumilast-for-patients-with-chronic-obstructive-pulmonary-disease-copd-and-chronic-bronchitis/ Wed, 29 Apr 2026 15:00:24 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-chf6001-dpi-with-roflumilast-for-patients-with-chronic-obstructive-pulmonary-disease-copd-and-chronic-bronchitis/ This clinical trial is focused on studying the effects of a new treatment for Chronic Obstructive Pulmonary Disease (COPD), specifically in patients who also have chronic bronchitis. The treatment being tested is called CHF6001 DPI, which is an inhalation powder containing the active substance tanimilast. The study will also involve a medication called Roflumilast (Daliresp®), which is available in tablet form. Some participants will receive a placebo, which looks like the real medication but does not contain any active ingredients.

The purpose of the study is to evaluate how effective and safe two different doses of CHF6001 DPI are when added to the usual maintenance therapy for COPD. This maintenance therapy typically includes a combination of inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), and long-acting muscarinic antagonists (LAMA). The study will last for 52 weeks, during which participants will be randomly assigned to different groups. Some will receive CHF6001 DPI along with their regular treatment, while others will receive Roflumilast or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment until the study is completed.

Throughout the study, participants will be monitored to see how the treatments affect their COPD symptoms, particularly the frequency and severity of flare-ups, also known as exacerbations. The study will also assess changes in lung function and quality of life. By the end of the study, researchers hope to determine whether adding CHF6001 DPI to the standard COPD treatment can help reduce the number of moderate and severe exacerbations in patients with COPD and chronic bronchitis.

]]>